Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Interleukin Inhibitors Market Grow Over the Forecast Period Based on Its Expected CAGR?
The market size of interleukin inhibitors has seen a swift increase in the recent past. Its growth is predicted to rise from a value of $42.93 billion in 2024 to $49.84 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.1%. The historic period’s growth can be linked to various factors such as an increased occurrence of autoimmune diseases, a heightened awareness of interleukin inhibitors, a rising demand for personalized medicine, an expanding elderly population, and a growing interest in biosimilars.
The market for interleukin inhibitors is projected to experience significant expansion in the coming years, eventually reaching a value of $96.66 billion by 2029 with a compound annual growth rate (CAGR) of 18.0%. This projected growth for the forecast period is due to several factors such as developing therapeutic indications, an increasing aging populace worldwide, the introduction of immunotherapy combinations, and a surge in research and development investments. Throughout the forecast period, leading trends would include oral interleukin inhibitors, advanced generation treatments, indications for children, extended access, and care geared towards the patient.
Which Macro and Microeconomic Factors Are Accelerating the Growth of the Interleukin Inhibitors Market?
The interleukin inhibitors market will be propelled by the rising count of experimental drugs for inflammation-related conditions like psoriasis, arthritis, and inflammatory bowel disease. Interleukin inhibitors aid in reducing inflammation-inducing cytokine activities, triggering innate immune reactions to protect the host from damage and to retain normal tissue balance. There are currently 48 molecules being investigated for the management of inflammatory diseases such as psoriasis and psoriatic arthritis. Of these, 20 molecules are in Phase III clinical trials. These increasing numbers of pipeline drugs are predicted to steer the growth of the interleukin inhibitors market upon their approval.
Request Your Free Interleukin Inhibitors Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=3469&type=smp
Who Are the Dominant Players Expanding Their Reach in the Interleukin Inhibitors Market?
Major companies operating in the interleukin inhibitors market include Sanofi S.A., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., AbbVie Inc., Sun Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Janssen Biotech Inc., Ortho Dermatologics, Amgen Inc., Celgene Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Seattle Genetics Inc., Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Astellas Pharma Inc., Ipsen Biopharmaceuticals Inc.
What Key Trends Are Currently Impacting the Interleukin Inhibitors Market’s Development?
The expiry of patents for biologic drugs opens up avenues for cheaper substitute drugs, known as biosimilars. Top businesses in the interleukin sector are channeling their efforts towards biosimilar development for interleukin inhibitors. Examples include the development of biosimilars for IL inhibitors like canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx) by Mabpharm, NeuClone Pharmaceuticals Ltd., Gedeon Richter, and Bio-Thera Solutions respectively. Despite the clear clinical advantages of biologics in treating psoriasis and other autoimmune diseases, many patients are not administered this treatment, with limited access to treatment often attributed to cost constraints. This, along with fast-paced advancements in biotechnology and analytical sciences ensuring biosimilars equivalency with biological drugs, fuels the biosimilars trend.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report
What Are the Core Categories and Segments in the Interleukin Inhibitors Market Driving Demand and Growth?
The interleukin inhibitors market covered in this report is segmented –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6, Other Types
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By IL-17: Secukinumab, Ixekizumab, Brodalumab
2) By IL-23: Ustekinumab, Guselkumab, Tildrakizumab
3) By IL-1: Anakinra, Canakinumab
4) By IL-5: Mepolizumab, Reslizumab, Benralizumab
5) By IL-6: Tocilizumab, Sarilumab
6) By Other Types: Other Interleukin Inhibitors
Which Regions Are Setting the Pace for Interleukin Inhibitors Market Growth?
The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
What Defines the Scope of the Interleukin Inhibitors Market?
Interleukin inhibitors refer to a substance used to suppress the immune system that prevents interleukins from working. Interleukins are a class of cytokines produced by white blood cells in response to infection (lymphocytes, monocytes, and macrophages). They are crucial to the control of the immune system.
Browse Through More Similar Reports By The Business Research Company:
Hypolipidemics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report
Diuretics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report
Antacids Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antacids-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
